---
figid: PMC6135718__nihms944158f6
figlink: /pmc/articles/PMC6135718/figure/F6/
number: F6
caption: EGFR (also known as ERBB1 and HER1) and ERBB2 (also known as HER2/neu) are
  the main therapeutic targets of currently available anti-angiogenic drugs. ERBB2
  lacks the ability to bind growth factor ligands and forms heterodimers with EGFR,
  ERBB3, or ERBB4. Monoclonal antibodies targeting the extracellular domain such as
  trastuzumab and pertuzumab prevent heterodimer formation, while others such as cetuximab,
  necitumumab, and panitumumab competitively inhibit EGFR ligand binding. Receptor
  tyrosine kinase inhibitors target the intracellular kinase domains and prevent signaling
  downstream of ligand-binding and dimer formation.
pmcid: PMC6135718
papertitle: 'Potential lymphangiogenesis therapies: learning from current anti-angiogenesis
  therapies - A review.'
reftext: Michael Yamakawa, et al. Med Res Rev. 2018 Sep;38(6):1769-1798.
pmc_ranked_result_index: '116058'
pathway_score: 0.7369119
filename: nihms944158f6.jpg
figtitle: 'Potential lymphangiogenesis therapies: learning from current anti-angiogenesis
  therapies - A review'
year: '2018'
organisms: Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6135718__nihms944158f6.html
  '@type': Dataset
  description: EGFR (also known as ERBB1 and HER1) and ERBB2 (also known as HER2/neu)
    are the main therapeutic targets of currently available anti-angiogenic drugs.
    ERBB2 lacks the ability to bind growth factor ligands and forms heterodimers with
    EGFR, ERBB3, or ERBB4. Monoclonal antibodies targeting the extracellular domain
    such as trastuzumab and pertuzumab prevent heterodimer formation, while others
    such as cetuximab, necitumumab, and panitumumab competitively inhibit EGFR ligand
    binding. Receptor tyrosine kinase inhibitors target the intracellular kinase domains
    and prevent signaling downstream of ligand-binding and dimer formation.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PDGFD
  - EGFR
  - MTOR
  - PDGFA
  - ERBB2
  - PDGFC
  - PDGFB
  - Tyrosine
  - Afatinib
  - Erlotinib
  - Gefitinib
  - Lapatinib
  - Vandetanib
  - Temsirolimus
  - Thalidomide
  - Lenalidomide
  - Axitinib
  - Nintedanib
  - Pazopanib
  - Regorafenib
  - Sorafenib
  - Pomalidomide
  - Sunitinib
genes:
- word: PDGF
  symbol: PDGF
  source: bioentities_symbol
  hgnc_symbol: PDGFD
  entrez: '80310'
- word: EGFR
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: PDGF
  symbol: PDGF
  source: bioentities_symbol
  hgnc_symbol: PDGFA
  entrez: '5154'
- word: ERBB2
  symbol: ERBB2
  source: hgnc_symbol
  hgnc_symbol: ERBB2
  entrez: '2064'
- word: PDGF
  symbol: PDGF
  source: bioentities_symbol
  hgnc_symbol: PDGFC
  entrez: '56034'
- word: PDGF
  symbol: PDGF
  source: bioentities_symbol
  hgnc_symbol: PDGFB
  entrez: '5155'
chemicals:
- word: Tyrosine
  source: ''
  identifier: ''
- word: Afatinib
  source: MESH
  identifier: C522924
- word: Erlotinib
  source: MESH
  identifier: C400278
- word: Gefitinib
  source: MESH
  identifier: C419708
- word: Lapatinib
  source: MESH
  identifier: C490728
- word: Vandetanib
  source: MESH
  identifier: C452423
- word: Temsirolimus
  source: MESH
  identifier: C401859
- word: Thalidomide
  source: MESH
  identifier: D013792
- word: Lenalidomide
  source: MESH
  identifier: C467567
- word: Axitinib
  source: MESH
  identifier: C503983
- word: Nintedanib
  source: MESH
  identifier: C530716
- word: Pazopanib
  source: MESH
  identifier: C516667
- word: Regorafenib
  source: MESH
  identifier: C559147
- word: Sorafenib
  source: MESH
  identifier: C471405
- word: Pomalidomide
  source: MESH
  identifier: C467566
- word: Sunitinib
  source: MESH
  identifier: C473478
diseases: []
figid_alias: PMC6135718__F6
redirect_from: /figures/PMC6135718__F6
figtype: Figure
---
